RxDoctor Payments Data

Charity Garber, APRN

Family · Perrysburg, OHNPI 1649841347

Payments from drug & device makers

$3,397in general payments, 2019–2025

Across 190 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$681
  • Novo Nordisk$590
  • Pfizer$404
  • Axsome Therapeutics, Inc.$280
  • AstraZeneca$251
  • Exact Sciences$145
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,30297%
  • Education$953%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,397 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$16,114
Medicare patients
88
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$39,360
JardianceEmpagliflozin20$25,830
TrulicityDulaglutide12$17,769
XareltoRivaroxaban24$17,496
JanuviaSitagliptin Phosphate18$15,362
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,812
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$9,473
Incruse ElliptaUmeclidinium Bromide11$3,731
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,192
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$2,922
Albuterol Sulfate HfaAlbuterol Sulfate117$2,733
Gabapentin163$2,057
Atorvastatin Calcium205$1,890
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen90$1,689
Pregabalin30$1,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$404$39,36055 claims
Boehringer IngelheimJardiance$47$25,83020 claims
Lilly USA, LLCTrulicity$87$17,76912 claims
Johnson & JohnsonXarelto$125$17,49624 claims
GSKTrelegy Ellipta, Incruse Ellipta$99$15,54422 claims
MerckJanuvia$13$15,36218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Perrysburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →